Benzinga News Feed

Posted by Unknown Minggu, 27 Oktober 2013 0 komentar

Benzinga News Feed


Short Interest In Harmony Gold Resumes Rise (EGO, HMY, KGC)

Posted: 26 Oct 2013 12:57 PM PDT

After fleeing from all the leading gold stocks in the previous period, short sellers found renewed interest in Harmony Gold Mining (NYSE: HMY) between the September 30 and October 15 settlement dates.

The number of shares sold short in AngloGold Ashanti (NYSE: AU),

Barron's Recap: The Snail Economy

Posted: 26 Oct 2013 12:55 PM PDT

This weekend in Barron's online: the case for a Great Stagnation, as well as the prospects for Kohl's, Furmanite, Walgreen and more.

Cover Story

"Slowing to a Crawl" by Jonathan R.

Short Sellers Pile On Applied Materials and STMicroelectronics (AMAT, MU, STM)

Posted: 26 Oct 2013 12:53 PM PDT

Among the leading semiconductor stocks, Applied Materials (NASDAQ: AMAT), Micron Technology (NASDAQ: MU) and STMicroelectronics (NYSE: STM) saw the most significant rises in short interest between the September

Top ETFs of the Week (GDX, EPOL, NUGT, URA)

Posted: 26 Oct 2013 12:50 PM PDT

The top ETFs in several categories this week are listed below.

Sector ETF – Market Vectors Gold Miners ETF (NYSE: GDX)

SLIDESHOW: Apple's First TV, New iPads And More From The Fourth Week Of October

Posted: 26 Oct 2013 12:48 PM PDT

The past week was nearly dominated by Apple's (NASDAQ: AAPL) many product announcements.

New iPads, new Mac Book Pros, new details on the Mac Pro -- the list went on and on.

The only thing missing was Apple's first TV set, though the rumor mill helped consumers cope with that.

The unconfirmed iWatch didn't make any noise thi

Bristol-Myers Presents Data on Nivolumab from Lung Cancer Cohort of Phase 1 Study at 15th World Conference on Lung Cancer

Posted: 26 Oct 2013 07:15 AM PDT

Bristol-Myers
Squibb Company (NYSE: BMY) today announced long-term follow-up
results (median follow up of 20.3 months) from the lung cancer cohort
(n=129) of the expanded Phase 1 dose-ranging study (003) of nivolumab,
an investigational PD-1 immune checkpoint inhibitor.

Synta Presents Positive One-Year Follow-up Results for GALAXY-1 Trial of Ganetespib in NSCLC at 15th World Conference on Lung Cancer

Posted: 26 Oct 2013 07:12 AM PDT

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation
of results from the GALAXY-1 trial, a global, randomized, multi-center
study designed to identify the patients with advanced non-small cell
lung adenocarcinoma most likely to benefit from second-line treatment

TERIMA KASIH ATAS KUNJUNGAN SAUDARA
Judul: Benzinga News Feed
Ditulis oleh Unknown
Rating Blog 5 dari 5
Semoga artikel ini bermanfaat bagi saudara. Jika ingin mengutip, baik itu sebagian atau keseluruhan dari isi artikel ini harap menyertakan link dofollow ke https://apk-1mobile.blogspot.com/2013/10/benzinga-news-feed_27.html. Terima kasih sudah singgah membaca artikel ini.

0 komentar:

Posting Komentar

Trik SEO Terbaru support Online Shop Baju Wanita - Original design by Bamz | Copyright of apk 1mobile.